Drug – bio-affecting and body treating compositions – Lymphokine
Reexamination Certificate
2011-06-14
2011-06-14
Landsman, Robert (Department: 1647)
Drug, bio-affecting and body treating compositions
Lymphokine
C514S001000, C514S001100
Reexamination Certificate
active
07959907
ABSTRACT:
The invention relates to the treatment of cancer. More specifically the invention shows that the anti-cancer activity in mammals can be augmented by administering to the mammalian host a combination of a synergistically effective amount of TNF and alfa-galactosylceramide.
REFERENCES:
patent: 4677063 (1987-06-01), Mark et al.
patent: 4677064 (1987-06-01), Mark et al.
patent: 2004/0127429 (2004-07-01), Tsuji
patent: 609437 (1999-07-01), None
patent: WO 97/12962 (1997-04-01), None
patent: WO 00/77168 (2000-12-01), None
patent: WO 2005/003167 (2005-01-01), None
patent: WO 2006/026389 (2006-03-01), None
patent: WO 2008/101951 (2008-08-01), None
Carswell EA, et al. Proc. Natl. Acad. Sci. 72(9):3666-3670, 1975.
Giaccone G, et al. Clinical Cancer Research, vol. 8:3702-3709, 2002.
Ten Hagen TLM, et al. Int. J. Cancer 87(6):829-837, 2000.
Nakagawa R, et al. Cancer Research 58:1202-1207, Mar. 15, 1998.
Mosteller RD. N. Engl. J. Med. Oct. 22, 1987;317(17):1098.
PCT International Search Report, PCT/EP2008/052055, dated Jun. 30, 2008.
Inui et al., Neutralization of tumor necrosis factor abrogates hepatic failure induced by alpha-galactosylceramide without attenuating its antitumor effect in aged mice, Journal of Hepatology, 2005, pp. 670-678, vol. 43.
Metelitsa et al., Expression of CD1d by myelomonocytic leukemias provides a target for cytotoxic NKT cells, Leukemia, 2003, pp. 1068-1077, vol. 17.
Nakui et al., Potentiation of antitumor effect of NKT cell ligand, alpha-galactosylceramide by combination with IL-12 on lung metastasis of malignant melanoma cells, Clinical & Experimental Metastasis, 2000, pp. 147-153, vol. 18.
Nishi et al., Synergistic Effect of KRN7000 with Interleukin-15, -7, and -2 on the Expansion of Human Valpha24+Vbeta11+T Cells In Vitro. Human Immunology, 2000, pp. 357-365, vol. 61.
DeVita et al., Chapter 13, Biologic Therapy with TNF: Systemic Administration and Isolation-Perfusion, Biologic Therapy of Cancer, Second Edition, 1995, pp. 329-345.
Lejeune et al., Efficiency of recombinant human TNF in human cancer therapy, Cancer Immunity, Mar. 22, 2006, pp. 1-17, vol. 6, p. 6.
PCT International Search Report, PCT/EP2004/051327, dated Dec. 9, 2004.
PCT Written Opinion, PCT/EP2004/051327, dated Dec. 9, 2004.
Brown et al., “Regulation of TRAF2 Signaling by Self-Induced Degradation,” The Journal of Biological Chemistry, May 31, 2002, pp. 19433-19438, vol. 277, No. 22.
Kavsak et al., “Samd7 Binds to Smurf2 to Form an E3 Ubiquitin Ligase that Targets the TGF-beta Receptor for Degradation,” Molecular Cell, Dec. 2000, pp. 1365-1375, vol. 6.
Legler et al., “Recruitment of TNF Receptor 1 to Lipid Rafts Is Essential for TNF-alpha-Mediated NF-kappaB Activation,” Immunity, May 2003, pp. 655-664, vol. 18.
Zapata et al., “TRAFI: Lord Without a RING,” Science's STKE, May 21, 2002, pp. 1-5, vol. 2002, No. 133.
Fraker et al., Chapter 13, Biologic Therapy with TNF: Systemic Administration and Isolation-Perfusion, Biologic Therapy of Cancer, Second Edition, 1995, pp. 329-345.
Nakagawa et al., Treatment of Hepatic Metastasis of the Colon 26 adenocarcinoma with an α-Galactosylceramids, KRN7000, Cancer Research, Mar. 15, 1998, pp. 1202-07, vol. 58.
Brouckaert Peter
Elewaut Dirk
Huyghe Leander
Landsman Robert
TraskBritt P.C.
Universiteit Gent
VIB VZW
LandOfFree
Method of treating cancer by combination therapy using TNF... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method of treating cancer by combination therapy using TNF..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method of treating cancer by combination therapy using TNF... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2645396